8-K: Arbutus Biopharma Announces Imdusiran Data Presentations at EASL Congress 2024

Arbutus Biopharma will present new data on its hepatitis B treatment, imdusiran, at the European Association for the Study of the Liver (EASL) Congress in June.

Summary

• Arbutus Biopharma has announced that two abstracts related to their drug imdusiran (AB-729) have been accepted for presentation at the EASL Congress 2024.
• One presentation will be a poster highlighting results from a study combining imdusiran with pegylated interferon alfa-2a, showing that 28% of subjects achieved HBsAg loss at the end of treatment with 4 or 6 doses of imdusiran plus 24 weeks of IFN.
• The other presentation will be an oral presentation on a study where imdusiran was followed by the immunotherapeutic VTP-300, which showed maintenance of lower HBsAg levels compared to imdusiran alone and allowed some subjects to discontinue NA therapy.
• The EASL Congress will take place in Milan, Italy from June 5-8, 2024.
• Imdusiran is an RNAi therapeutic designed to reduce HBV viral proteins and antigens, and is currently in multiple Phase 2a clinical trials.

Sentiment

Score: 7

Explanation: The document presents positive clinical data for imdusiran, indicating potential for the drug. However, it also acknowledges ongoing studies and risks, which tempers the overall sentiment.

Positives

• The data presented at EASL shows that imdusiran, in combination with other therapies, can lead to HBsAg loss in some patients.
• The combination of imdusiran and VTP-300 shows promise in maintaining lower HBsAg levels and allowing some patients to discontinue NA therapy.
• Imdusiran has shown to be generally safe and well-tolerated in clinical trials.
• The company is actively advancing imdusiran through multiple Phase 2a clinical trials.

Negatives

• The study combining imdusiran with 12 weeks of IFN did not result in any subjects achieving HBsAg loss.
• The data presented is from ongoing studies, and additional data is still to be released.

Risks

• Clinical trials may be more costly or take longer to complete than anticipated.
• The company may not receive the necessary regulatory approvals for its products.
• Economic and market conditions may worsen, impacting the company's operations.
• Market shifts may require a change in strategic focus.

Future Outlook

The company anticipates releasing additional end-of-treatment data, durability of end-of-treatment HBsAg loss, and preliminary immunology data from the ongoing studies. They also plan to continue the clinical development of their product candidates.

Industry Context

The announcement is relevant to the broader biopharmaceutical industry focused on developing treatments for chronic hepatitis B, a significant global health concern. The company is leveraging RNAi technology, which is a growing area of interest in drug development.

Comparison to Industry Standards

• Gilead Sciences is a major player in the HBV space with drugs like Vemlidy, which is a nucleotide analog that suppresses HBV DNA but does not address the surface antigen.
• Assembly Biosciences is developing core inhibitors that target the HBV core protein, aiming to reduce viral replication and antigen production.
• Vir Biotechnology is working on immunotherapies and antibodies to stimulate the immune system to clear the virus.
• Arbutus' approach with imdusiran, an RNAi therapeutic, is unique in its direct targeting of all HBV viral proteins and antigens, including surface antigen, which is a key differentiator from many other treatments.

Stakeholder Impact

• Shareholders may react positively to the clinical data presented.
• Patients with chronic hepatitis B may benefit from the development of new treatment options.
• The company's employees are involved in the ongoing clinical trials and development of the drug.

Next Steps

• The company will present the poster and oral presentations at the EASL Congress 2024.
• Additional end-of-treatment data, durability of end-of-treatment HBsAg loss, and preliminary immunology data will be presented.
• The company will continue the clinical development of imdusiran and AB-101.

Key Dates

Keywords

Arbutus Biopharma, Imdusiran, AB-729, Hepatitis B, HBV, EASL Congress, RNAi, VTP-300, HBsAg, Clinical Trials